Skip to main content

Table 2 The treatment characteristics of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients

From: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

Medicines

Cases (n)

Taxanes

  

Docetaxel

52

(33.8%)

Albumin-bound taxanes

87

(56.5%)

Liposomal taxanes

15

(9.7%)

PD-1 Inhibitors

  

Pembrolizumab

64

(41.6%)

Toripalimab

27

(17.5%)

Camrelizumab

21

(13.6%)

Sindilizumab

19

(12.3%)

Tislelizumab

16

(10.4%)

Penpulimab

7

(4.5%)

Other medicines Combined

  

Platinum-based

131

(85.1%)

Cisplatin

119

(77.3%)

Nedaplatin

12

(7.8%)

Cetuximab

7

(4.5%)

Nimotuzumab

4

(2.6%)

Anlotinib

2

(1.3%)

Capecitabine

1

(0.6%)

No Other Medicines Combined

17

(11.0%)

Previous Radiotherapy

  

Yes

32

(20.8%)

No

122

(79.2%)

Subsequent Radiotherapy

  

Yes

48

(31.2%)

No

106

(68.8%)

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us